Source: CureToday articles
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
Recent Content
- AAN 2025: Pharmacists Play Critical Role in Monitoring, Managing Lecanemab Therapy
- Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
- Risk of lymphoid malignancy associated with cancer predisposition genes
- Large-scale human myeloma cell line small molecule compound screen dataset
- Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
- PCV10 Elicits Durable Immune Response in T2D, Though Response Remains Inferior to Non-Diabetics
- AAN 2025: Insights on Pediatric Multiple Sclerosis Treatment and Management
- Illuminating Compassion in Cancer Care
- Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
- Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders